Compare Costco Wholesale Corporation (COST) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Sanofi SA — how do they compare? Costco Wholesale Corporation trades at $921.16 (market cap $408.78B), while Sanofi SA trades at $43.05 (market cap $102.91B). The key difference: Costco Wholesale Corporation is far larger — about 4× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.6%). Which is the better fit depends on your goals.
| COST | SNY | |
|---|---|---|
Market Cap | $408.78B | $102.91B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $52.34 |
52-Week Low | $849.63 | $41.33 |
Enterprise Value | $396.92B | $119.39B |
Dividend Yield | 0.64% | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $926.43, up 1.11% with strong fundamentals including 11.3% March sales growth and consistent earnings beats. The stock faces technical headwinds with bearish moving averages but maintains solid profitability with $8.1B net income and expanding margins. Recent membership fee increases and warehouse expansion support long-term growth, though high valuation multiples present near-term pressure.
Outlook remains positive with analyst consensus at $1,120 price target (65% buy ratings), but investors should monitor valuation sustainability amid technical weakness. Key risks include competitive pressures and economic sensitivity, while institutional accumulation and strong cash flow generation provide fundamental support.
SNY trades at $44.00, up 1.15% with a bullish technical signal. Recent FDA approvals for Sarclisa and Nexviazyme highlight pipeline strength. Q1 2026 EPS beat expectations at $1.10 versus $1.06. Revenue grew to $46.72B in 2025 with net income margin of 15.95%. Analyst consensus is mixed with 44% buy ratings. The stock shows solid profitability with ROE at 10.29% and manageable debt levels.
Outlook is positive driven by drug approvals and earnings beats, but EU antitrust probes pose regulatory risks. Valuation at P/E 19.51 is reasonable versus peers. Institutional sentiment is cautious with 52% hold ratings. Key catalysts include Q2 2026 results and Sarclisa commercial rollout. Risks include competition and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
